SUMO治疗缺血性中风的治疗方法
Paramesh Karandikar1, Jakob V E Gerstl2, Ari D Kappel2,3
1T. H. Chan School of Medicine, University of Massachusetts, Worcester, MA 01655, USA.
Pharmaceuticals (Basel, Switzerland)
|May 27, 2023
概括
这种小型的,类似于全方位素的修饰剂 (SUMO) 途径显示出神经保护作用,为急性脑缺血提供了有前途的治疗标. 针对SUMOylation的小分子正在临床前模型中得到验证.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 这种小型的,类似于泛素的修饰剂 (SUMO) 途径调节关键的生物过程,包括哺乳动物的应激反应.
- SUMOylation已经证明了神经保护作用,特别是在冬眠中的松鼠中观察到的.
- 它在神经元缺血,离子梯度和神经干细胞预调中的作用突显了治疗潜力.
研究的目的:
- 在脑缺血的背景下,审查SUMOylation途径的当前知识.
- 突出针对SUMOylation治疗急性脑性缺血的翻译潜力.
主要方法:
- 文献综述总结了关于SUMOylation和脑缺血的现有研究.
- 讨论高通量查和临床前模型的发现.
主要成果:
- SUMOylation与控制神经元对缺血的反应有关.
- 调高SUMOylation的小分子已经在临床前模型中被识别和验证.
- 该SUMO途径在维持离子梯度和神经干细胞预调中发挥作用.
结论:
- 该SUMOylation途径是急性脑缺血的一个有前途的治疗点.
- 对SUMOylation向分子的进一步研究和开发可能会导致针对脑缺血的新型治疗方法.
相关概念视频
Regulation of Stroke Volume
3.3K
The regulation of stroke volume, which is the amount of blood the heart pumps out during each heartbeat, is critical for maintaining a healthy circulatory system. Stroke volume is influenced by three main factors: preload, contractility, and afterload.
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
3.3K
Ischemic Heart Disease: Overview
1.4K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
225
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
225
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
205
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
205
Atherosclerosis III: Management
16
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
354
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
354


